03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *
Apo-Terbinafine : | |
Type | Medicine Authorised |
Originator | Lamisil Tablets 250mg |
Agent | Promopharm |
Distributor | Promopharm |
Laboratory | Apotex |
Responsible Party | Apotex Inc |
Origin | Canada |
Manufacturer | Apotex Inc |
Manufacturing Type | G |
Origin | Canada |
ATC | D01BA02 |
Apo-Terbinafine :
Apo-Terbinafine :
Apo-Terbinafine :
Apo-Terbinafine :
Apo-Terbinafine :
Hazard Level |
---|
◼ Major |
◼ Moderate |
◼ Minor |
◼ Safe |
Apo-Terbinafine :
Frequency | Percentage |
---|---|
Very Common | ≥ 1/10 |
Common | ≥ 1/100 - < 1/10 |
Uncommon | ≥ 1/1,000 - < 1/100 |
Rare | ≥ 1/10,000 - < 1/1,000 |
Very Rare | < 1/10,000 |
Unknown | Cannot be Estimated |
Effect | Frequency |
---|---|
Abdominal bloating (Meteorism) | Very Common |
Abdominal pain | Very Common |
Acute generalised exanthematous pustulosis (AGEP) | Very rare |
Ageusia (Taste loss) | Uncommon |
Agranulocytosis | Very rare |
Alopecia | Very rare |
Anaemia | Not known |
Anaphylactic reactions | Not known |
Anaphylactoid reactions | Very rare |
Angioedema (Angioneurotic oedema) (Quincke oedema) | Very rare |
Anosmia (smell loss) | Not known |
Anxiety | Not known |
Arthralgia (Pain joint) (Joint ache) | Very Common |
Blood creatine phosphokinase increased | Not known |
Cephalea | Common |
Cholestasis | Not known |
Cutaneous lupus erythematosus | Very rare |
Decreased appetite | Very Common |
Depression | Not known |
Diarrhoea (Diarrhea) | Very Common |
Dyspepsia | Very Common |
Erythema multiforme | Very rare |
Fatigue | Very rare |
Flu-like syndrome | Not known |
Hearing loss | Not known |
Hepatic enzyme increased | Rare |
Hepatic failure (Hepatic insufficiency) (Liver failure) | Rare |
Hepatitis | Not known |
Hypoacusis | Not known |
Hypoesthesia | Very rare |
Hypogeusia | Uncommon |
Jaundice | Not known |
Lightheadedness | Very rare |
Lyell Syndrome (Toxic epidermal necrolysis) | Very rare |
Myalgia | Very Common |
Nausea | Very Common |
Neutropenia | Very rare |
Pancreatitis | Not known |
Pancytopenia | Very rare |
Paraesthesia (paresthesia) | Very rare |
Photosensitivity reaction | Uncommon |
Polymorphic light eruption | Uncommon |
Psoriasis aggravated (Psoriasis flare-up) | Very rare |
Pyrexia | Not known |
Rash psoriaform | Very rare |
Rhabdomyolysis | Not known |
Serum sickness-like reaction | Not known |
Skin Eruption | Very Common |
Stevens-Johnson syndrome | Very rare |
Systemic lupus erythematosus | Very rare |
Thrombocytopenia (Thrombopenia) | Very rare |
Tinnitus | Not known |
Urticaria | Very Common |
Vasculitides | Not known |
Weight decreased (Weight loss) | Not known |
Apo-Terbinafine :
▲ Most Expensive |
▼ Least Expensive |
P.P. = | Public Price |
P/U = | Price Per Unit |
- Products with same active ingredients |
- Products with same strength |
- Products with same route of administration |
NB : Products With Same Indication |
Different Units By MoH Code
Apo-Terbinafine MoH 5589 :
Form | Tablet |
Packaging | Blisters |
Package Size | Box of 30 |
Strength | 250mg |
Storage Condition | 15-30°C protect from light |
Public Price | 1409690.78 L.L. |
Stratum | A2 |
NSSF | ✔ |
Quarantine | ✘ |
Reg. Number | 221407/08 |
Submission date | 01/01/2008 |
Registration Year | 2009 |
Barcode | 771313139281 |
Price Comparison
● Country: | Belgium | |
● Package Size: | 14 | |
● Public Price: | 19.53 EUR | ( 1,891,988.28 LBP ) |
● Pack size unit used: | 14 | |
● Cost/Unit: | 1,395 EUR | ( 96,876.00 LBP ) |
● Reference: | cbip | |
● Pricing Date: | 10/09/2019 | |
● Type: | Medicine Non Marketed |
● Country: | Lebanon | |
● Form: | Tablet | |
● Package Size: | Box of 30 | |
● Public Price: | 1409690.78 LBP | ( 1,409,690.78 LBP ) |
● Pack size unit used: | 30 | |
● Cost/Unit: | 46989,69 LBP | ( 46,989.00 LBP ) |
● Pricing Date: | 13/06/2024 |
● Country: | UK |
● Package Size: | 28 |
● Reference: | DMD |
● Pricing Date: | 08/03/2021 |
● Type: | Medicine Withdrawn |
You have to register to view this info
Drop File